Greenwich LifeSciences, Inc. (GLSI) NASDAQ

12.00

+0.22(+1.87%)

Updated at March 14 04:00PM

Currency In USD

Greenwich LifeSciences, Inc.

Address

Building 14

Stafford, TX 77477

United States of America

Phone

832 819 3232

Sector

Healthcare

Industry

Biotechnology

Employees

3

First IPO Date

September 25, 2020

Key Executives

NameTitlePayYear Born
Mr. Snehal S. PatelChief Executive Officer, Chief Financial Officer & Director1.09M1963
Dr. Christine T. Fischette Ph.D.Vice President of Business Development01951
Mr. Eric RotheFounder & Independent Director01975
Dr. Frank Joseph Daugherty M.D.Chief Medical Officer & Director01950
Dr. Jaye L. Thompson Ph.D.Vice President Clinical & Regulatory Affairs01966

Description

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.